Gilead Sciences, Inc. (NASDAQ:GILD) is among the 12 Most Profitable NASDAQ Stocks to Buy Right Now. On January 27, Truist Securities lifted its price target on the stock to $145 from $140, while maintaining a Buy rating.
According to Tipranks, Truist told investors in a research note that it was revising estimates for YEZTUGO, a prescription drug to lower HIV-1 risk, heading into fourth-quarter earnings. The firm is also adjusting certain timelines following recent updates on upcoming launches, including BIC/LEN and Hepcludex in the United States.
On the same day, Citigroup also provided an update on Gilead Sciences, Inc.. The firm lifted its price target on the stock to $156 from $140, while keeping a Buy rating.
Citi’s adjustment came as part of the firm’s broader Q4 preview of biopharmaceutical stocks. The bank expects achievable estimates and reduced policy risk to create a promising environment for the group this year.
Gilead Sciences, Inc. is a biopharmaceutical company engaged in the development of medicines to prevent and treat various life-threatening diseases, including HIV, viral hepatitis, and cancer.
READ NEXT: 10 Best Defense Stocks to Buy in the S&P 500 and 14 Best Booming Stocks to Buy Right Now.
